COMMUNIQUÉS West-GlobeNewswire

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN
06/06/2025
Robust proteinuria reduction and stable kidney function were maintained across a broad population of patients No new safety signals were observed New data presented at late-breaking session at the European Renal [...]
Biomerica Appoints Eric B. Chin to Board of Directors and Audit Committee Chair
06/06/2025
Mr. Chin brings over 20 years of financial experience across public and private healthcare organizations Mr. Chin currently serves as CFO of Akido Labs where he successfully helped raise $60 million in a recent [...]
Soligenix Highlights Dr. Ellen Kim’s Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials
06/06/2025
PRINCETON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat [...]
Immix Biopharma Attends FDA CEO Forum in Washington DC
06/06/2025
– Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. Makary, M.D., M.P.H. – LOS ANGELES, CA, June 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ” [...]
President of the Association of American Physicians and Surgeons (AAPS) Writes, ‘Let’s Make America Healthy Again’
06/06/2025
TUCSON, Ariz., June 06, 2025 (GLOBE NEWSWIRE) -- The Make America Healthy Again (MAHA) project is a monumental task, writes Erika L. LeBaron, DO., M.S.N., in the summer issue of the Journal of American Physicians and [...]
Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders
06/06/2025
TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ( "Spectral" or the "Company" ) (TSX: EDT) , a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced [...]
Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model
06/06/2025
Data featured in oral presentation and poster session at 48 th European Cystic Fibrosis Conference WALTHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage [...]
BioNTX to Join Strategic Partners at BIO International Convention, Showcasing North Texas as a Converging Life Sciences Powerhouse
06/06/2025
DALLAS, June 06, 2025 (GLOBE NEWSWIRE) -- BioNTX , the leading voice of the bioscience and healthcare innovation ecosystem in North Texas, is proud to announce its attendance at the upcoming 2025 BIO International [...]
European Commission Approves Duvyzat for the Treatment of Duchenne Muscular Dystrophy
06/06/2025
Now approved in the EU, Duvyzat offers an important treatment option for delaying Duchenne muscular dystrophy (DMD) disease progression Duvyzat is an orally administered treatment for DMD in patients 6 years and older [...]
Venus Concept Announces Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
06/06/2025
$1.15 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the exercise in full of unregistered short-term warrants TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Venus Concept [...]
Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
06/06/2025
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 06 juin 2025 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui [...]
Press release: Transparency Notification from Shareholders
06/06/2025
Transparency Notification from Shareholders Ghent, Belgium – 6 June 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the treatment of drug-resistant fluid [...]
Polpharma Group soutient l’action urgente de l’UE visant à garantir l’accès aux médicaments et à renforcer la souveraineté pharmaceutique européenne
06/06/2025
En tant que membre de l’association Medicines for Europe, Polpharma Group se joint aux leaders du secteur pour appeler les Premiers ministres de l’UE à adopter un plan d’action pharmaceutique en cinq points destiné à [...]
Rectify Pharma Presents Translational Data Demonstrating Improvements in Kidney Function and Reductions in Vascular Calcification at ERA 2025
06/06/2025
Potent, selective ABCC6-targeting positive functional modulator (PFM) improved multiple markers of renal function in animal models of chronic kidney disease (CKD) PFM improved inorganic pyrophosphate (PPi) efflux via on [...]
Denovo Biopharma Announces Formation of Neuroscience Scientific Advisory Board to Advance Precision Medicine in Depression
06/06/2025
- Scientific Advisory Board brings together distinguished experts in neuroscience to support Denovo’s CNS development programs, including the Phase 3-ready lead program, biomarker-guided DB104 (liafensine) in treatment- [...]
BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries
06/06/2025
ORLADEYO® (berotralstat) now reimbursed in the Netherlands RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive [...]
ProPhase Labs Announces Formation of Clinical Science Advisory Board to Accelerate Commercialization of BE-SmartTM Esophageal Disease Diagnostic Platform
06/06/2025
UNIONDALE, NY, June 06, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced the formation of its [...]
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)
06/06/2025
SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein [...]
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
06/06/2025
– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England [...]

Pages